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ABSTRACT
Background. The objectives of this study were to elicit the pref-
erences of patients with multiple myeloma regarding the possi-
ble beneﬁts and risks of cancer treatments and to illustrate
how such data may be used to estimate patients’ acceptance of
new treatments.
Patients and Methods. Patients with multiple myeloma from
the cancer charity Myeloma UK were invited to participate in
an online survey based on multicriteria decision analysis and
swing weighting to elicit individual stated preferences for the
following attributes: (a) 1-year progression-free survival (PFS,
ranging from 50% to 90%), (b) mild or moderate toxicity for 2
months or longer (ranging from 85% to 45%), and (c) severe or
life-threatening toxicity (ranging from 80% to 20%).
Results. A total of 560 participants completed the survey. The
average weight given to PFS was 0.54, followed by 0.32 for
severe or life-threatening toxicity and 0.14 for mild or moderate
chronic toxicity. Participants who ranked severe or life-
threatening toxicity above mild or moderate chronic toxicity
(56%) were more frequently younger, working, and looking
after dependent family members and had more frequently
experienced severe or life-threatening side effects. The amount
of weight given to PFS did not depend on any of the collected
covariates. The feasibility of using the collected preference data
to estimate the patients’ acceptance of speciﬁc multiple
myeloma treatments was demonstrated in a subsequent deci-
sion analysis example.
Conclusion. Stated preference studies provide a systematic
approach to gain knowledge about the distribution of preferen-
ces in the population and about what this implies for patients’
acceptance of speciﬁc treatments.The Oncologist 2017;22:1–8
Implications for Practice: This study demonstrated how quantitative preference statements from a large group of participants can
be collected through an online survey and how such information may be used to explore the acceptability of speciﬁc treatments
based on the attributes studied. Results from such studies have the potential to become an important new tool for gathering
patient views and studying heterogeneity in preferences in a systematic way, along with other methods, such as focus groups and
expert opinions.
INTRODUCTION
Beneﬁt-risk assessment is the cornerstone of therapeutic and
regulatory decisions. This requires value judgments regarding
the relative importance of the expected favorable and unfavor-
able effects associated with treatment. While the regulator’s
role is to make decisions that are in the best interest of the
patient, it is being increasingly recognized that patients,
physicians, and regulators may have different views on the
importance of one treatment outcome compared with another
(e.g., when the impact of a certain treatment outcome on a
patient’s daily life is hard to understand without experience of
living with the condition). Information about how individual
patient preferences are distributed in the target population
could help rendering the decision-making in such preference-
sensitive settings more patient-centered [1].
The European Medicines Agency (EMA) has developed a
framework for interaction with patients and consumers and
their organizations [2]. One of the objectives of the frame-
work is to facilitate participation of patients in beneﬁt-risk
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evaluation and to explore how methods for eliciting patient
preferences can complement other methods for gathering
patient views, such as focus groups and asking a few
patients to provide input during the assessment. To this
end, the EMA previously conducted a pilot study in which
individual preferences about hypothetical cancer treat-
ments were elicited from a diverse group of patients, health
care professionals, and regulators [3]. While the results
from that study suggested that collecting preference data
through an online survey based on multicriteria decision
analysis (MCDA) and swing weighting was feasible and
could provide some indication as to how preferences might
vary across stakeholders, it also became apparent that there
was considerable heterogeneity in how individual partici-
pants valued the attributes of treatments included in the
survey. However, because subject characteristics were not
collected, it was not possible to further characterize the
within-group variability observed in the study. To explore
this aspect, we conducted the present study in the area of
relapsed or refractory multiple myeloma with a larger
sample of patients from the cancer charity Myeloma UK.
First, we describe the variation in individual preferences
in the surveyed population and the extent to which this
variation can be explained by demographic and clinical
characteristics. Next, we use a real example to illustrate
how the elicited preference statements can be combined
with data on progression-free survival (PFS) and toxicity
from a randomized clinical trial to estimate the acceptability
of two treatments for patients with multiple myeloma (ixa-
zomib in combination with lenalidomide and dexametha-
sone against placebo in combination with lenalidomide and
dexamethasone).
MATERIALS AND METHODS
To elicit individual patient preferences for different attributes of
treatments of multiple myeloma, we conducted an online
survey based on MCDA. A schematic representation of the
approach used for this study is provided in Figure 1. First, the
attributes and attribute levels to include in the survey were
selected with the help of a focus group, and a questionnaire
was developed to elicit statements regarding the relative
importance of those attributes from prospective participants.
Subsequently, the survey was administered to patients from
the cancer charity Myeloma UK. Next, the ordinal preference
statements collected in the survey were transformed into
subject-level estimates of the part worth associated with each
attribute level by applying the procedure described in the sup-
plemental online material. This was followed by an empirical
analysis phase in which the variation in individual preferences
was described and further analyzed and a decision analysis
phase in which the distribution of the preferences in the sur-
veyed population was combined with data from a clinical trial
to estimate the acceptability of two treatment regimens.
Attributes and Attribute Levels
The attributes and attribute levels that were included in the sur-
vey are summarized in Table 1. PFS, operationalized as the prob-
ability of being progression-free for 1 year or longer, was
selected as the measure of treatment beneﬁt. Following our
previous pilot study [3], the adverse events were aggregated
into two broad categories based on their duration and amount
of interference with a patient’s usual or daily activities.
In the questionnaire, PFS was explained as “the time during
which treatment can induce and maintain a remission or at
least delay the growth of cancer and worsening of symptoms
and can delay the need for additional treatment for some
time.” Mild or moderate side effects were explained as “side
effects that do not immediately require medical intervention
but whose symptoms are likely to interfere with normal daily
activities. Examples include moderate levels of fatigue (not
relieved by rest), diarrhoea (up to 6 stools per day), and moder-
ate pain.” Severe or life-threatening side effects were explained
Figure 1. Schematic representation of the steps taken in this study. In step 1 (Design), a model is set up with the help of a focus group,
with attributes of interest and ranges on which preferences will be collected. In step 2 (Elicit), a questionnaire is used ﬁrst to elicit the
ordinal ranking of the attributes considering the full range of alternatives; then choice matching is used to elicit trade-offs by comparing
different levels for pairwise attributes, and the process is repeated for all attributes. In step 3 (Analyze), the data collected in the survey
are transformed into a set of weights reﬂecting the relative importance of the considered attributes. In Step 4 (Apply), the elicited prefer-
ences are combined with data from a clinical trial to assess acceptability of two treatments based on the individual elicited weights.
Abbreviations: G1–2, mild or moderate toxicity; G3–4, severe or life-threatening toxicity; PFS, progression-free survival.
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as “side effects that require medical intervention and whose
symptoms strongly interfere with normal daily activities. Hospi-
talisation, dose reduction, or treatment discontinuation may be
required. Examples include severe pain (limiting daily activities),
skin problems requiring intravenous antibiotics, inﬂammation
affecting eating and swallowing, diarrhoea (7 or more stools
per day), and incontinence.”
Preference Model
In MCDA, a participant’s preferences for different combinations
of the attribute levels are represented by means of a mathe-
matical function that assigns to each combination of attribute
levels a preference score reﬂecting the relative desirability of
this combination of attribute levels compared with all other
combinations of attribute levels. These scores are normalized
so that the least preferred combination of attribute levels (PFS,
50%; mild or moderate chronic toxicity, 85%; severe or life-
threatening toxicity, 80%) is assigned a value of 0 and the most
preferred combination of attribute levels (PFS, 90%; mild or
moderate chronic toxicity, 45%; severe or life-threatening toxic-
ity, 20%) a value of 1. How the preference scores of the other
combinations of attribute levels are calculated depends on the
shape of the value function. For this study, we assumed this
function to be additive, so that the preference score (overall
value) assigned to a combination of attribute levels is the sum
of the part worth (partial values) associated with each of the
individual attribute levels in this combination. Three combina-
tions of attribute levels of particular interest are the corner
point combinations: (a) PFS, 90%; mild or moderate chronic
toxicity, 85%; severe or life-threatening toxicity, 80%; (b) PFS,
50%; mild or moderate chronic toxicity, 45%; severe or life-
threatening toxicity, 80%; and (c) PFS, 50%; mild or moderate
chronic toxicity, 85%; severe or life-threatening toxicity, 20%.
The preference scores associated with these corner point com-
binations reﬂect how important the “swing” (improvement)
fromworst to best on one attribute is compared with the swing
from worst to best on the other attributes and can therefore
be seen as a measure of the relative importance of the attrib-
utes. The preference score associated with the corner point
combination for which an attribute is at its most preferred level
is called the weight of that attribute. By deﬁnition, the weights
are equal to the part-worth values associated with the attrib-
utes’ most preferred levels, which are non-negative and sum to
1. A more detailed discussion of the preference model used in
this study can be found in the supplemental online material.
Questionnaire Instrument
The development of the questionnaire went through several
phases. First, the overall context of the survey was discussed in
a focus group with patients with multiple myeloma, clinicians,
advocates, and regulators. Feedback was obtained on the
appropriateness of the chosen attributes, the wording of the
electronic consent, elicitation questions, the explanatory text,
the complexity of the exercise, and other issues that could
affect a patient’s ability or willingness to participate in the
study. Subsequently, a ﬁrst version of the online questionnaire
was developed and pretested with a different group of patients
with multiple myeloma, from whom we received detailed
comments regarding the level of cognitive burden, clarity of
the instructions and explanations provided, and ease of use
of the elicitation software. Based on this feedback, a revised
version of the questionnaire was developed.
A full script of the ﬁnal version of the questionnaire can be
found in the supplemental online material. In short, to assess
the attribute weights, participants were ﬁrst asked to rank the
swing from worst to best for each of the three attributes from
most important to least important. For example, one partici-
pant, say Mr. Smith, may feel that increasing the probability of
being progression-free for 1 year or longer from 50% to 90% is
more important than decreasing the probability of experiencing
severe or life-threatening toxicity from 80% to 20%, and that
this in turn is more important than decreasing the probability
of experiencing mild or moderate chronic toxicity from 85% to
45%. For the parameterization of Mr. Smith’s preference model,
we then know that (a) the weight attached to PFS must be
higher than the weight attached to severe or life-threatening
toxicity and the weight attached to mild or moderate chronic
toxicity and (b) the weight attached to severe or life-
threatening toxicity must higher than the weight attached to
mild or moderate chronic toxicity. Subsequently, starting from
a situation in which the most important attribute (PFS for Mr.
Smith, but this could be different for other participants) is at its
worst value and the second most important attribute (severe
or life-threatening toxicity for Mr. Smith) is at its best value, par-
ticipants were asked to determine to what extent the perform-
ance on the former needs to be improved to offset a swing
from best to worst on the latter. This was assessed in an indirect
manner by asking the participants to respond to two pairwise
comparison questions that narrowed the interval in which this
indifference value must lie to a fraction of the attribute’s full-
scale range, as described in more detail in Postmus et al. [3].
For example, from these two pairwise comparison questions,
we may learn that for Mr. Smith to accept an increase in the
probability of experiencing severe or life-threatening toxicity
from 20% to 80%, the probability of being progression-free for
1 year or longer must increase from 50% to somewhere
between 70% and 80%. For the parameterization of Mr. Smith’s
preference model, it must then hold that the weight attached
to severe or life-threatening toxicity is between the part worth
Table 1. Attributes and attribute levels considered in the survey
Attribute Deﬁnition Levels
Progression-free survival Probability of being progression-free
for 1 year or longer
50%, 60%, 70%, 80%, 90%
Mild or moderate
chronic toxicity
Probability of experiencing mild to
moderate side effects for two
months or longer
45%, 55%, 65%, 75%, 85%
Severe or life-threatening
toxicity
Probability of experiencing severe to
life-threatening side effects
20%, 35%, 50%, 65%, 80%
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associated with a 1-year PFS of 70% and the part worth associ-
ated with a 1-year PFS of 80%. Next, this question format was
repeated to assess howmuch participants were willing to trade
between the second most important and the least important
attribute. Note that the exact trade-offs considered in these
four pairwise comparison questions varied from one participant
to another depending on how they rank ordered the three
attributes and on how they answered preceding pairwise com-
parison questions. To assess the shape of the partial value func-
tions, participants were asked to rank the increases in value
associated with going from one attribute level to another from
greatest to smallest, allowing them to assign the same rank to
those improvements that they considered to be equally valua-
ble. These questions were the same for all study participants. In
addition to the above preference elicitation questions, the sur-
vey also contained questions to collect demographic and clini-
cal information and open-ended questions to collect
participant feedback about the study.
Participant Recruitment
Patients with multiple myeloma who had given prior permis-
sion to receive mailings were invited by the cancer charity
Myeloma UK to participate in the study. A prelaunch announce-
ment of the study was also posted on the Myeloma UKwebsite
together with an option to register for the study mailing. On
June 3, 2016, e-mail invitations with a personal link to the
online questionnaire were sent to a total of 2,204 individuals.
This was followed by a reminder email on June 10, 2016, and
the survey was closed on June 17, 2016.
Empirical Analysis
The subject-level part-worth values associated with each of the
attribute levels were summarized using boxplots, and the joint
distribution of the attribute weights was presented graphically
on a ternary plot. Subsequently, the variation in the weights
was further characterized by describing the proportion of par-
ticipants falling in different segments of the ternary plot.
Finally, to explore whether weights differed signiﬁcantly across
different subgroups of participants deﬁned by demographic
and clinical characteristics, chi-square tests were performed
with an alpha of 5% as the selected level of signiﬁcance. All
these analyses were exploratory.
Decision Analysis Example
A recently approved drug for multiple myeloma was chosen
to illustrate how the elicited preference statements can be
combined with data on PFS and toxicity from a randomized
clinical trial to estimate the acceptability of two treatments
for patients with multiple myeloma. Ixazomib is an oral pro-
teasome inhibitor that has recently been approved in the
European Economic Area for use in combination with lenali-
domide and dexamethasone for the treatment of adult
patients with multiple myeloma who have received at least
one prior therapy. To estimate the proportion of patients
ranking the ixazomib-containing combination above the
standard regimen, we conducted a stochastic multicriteria
acceptability analysis [4] with the preference model parame-
ters sampled from the empirical distribution of these parame-
ters in the surveyed population and treatment effect
estimates obtained from a randomized controlled trial of ixa-
zomib or placebo in combination with a standard regimen of
lenalidomide and dexamethasone in patients with relapsed,
refractory, or relapsed and refractory multiple myeloma [5].
The proportion of patients with a PFS of 1 year or longer was
estimated from the ﬁnal statistical analysis dataset for this
study endpoint (data cutoff: October 2014). The proportion of
patients experiencing mild or moderate chronic toxicity and
the proportion of patients experiencing severe or life-
threatening toxicity were estimated from the latest safety
analysis dataset (data cutoff: July 2015). For mild or moderate
chronic toxicity, all National Cancer Institute Common Toxicity
Criteria for Adverse Events mild (grade 1) and moderate
(grade 2) treatment-related adverse events (i.e., adverse
events at least possibly related, as determined by investigator,
to any of the three agents in the combination) with a resolu-
tion date more than 60 days after toxicity start date or unre-
solved at the time of the data cutoff but with toxicity start
date at least 60 days before data cutoff were included in the
estimation of this event rate. For severe or life-threatening




Of the 2,204 individuals who received the email invitation, 795
(36.1%) clicked through to the online questionnaire. Of those
visiting the survey website, 650 (81.8%) provided electronic
consent after reading the study information sheet and 563
(70.8%) completed the full questionnaire, resulting in a 25.5%
response rate and an 86.6% completion rate. Two participants
withdrew their consent after completion of the questionnaire,
and one participant was excluded due to declaring not to have
multiple myeloma, resulting in a study population of 560
participants.
Demographic and clinical characteristics of the survey par-
ticipants are provided in Table 2. Participants were most fre-
quently between 61 and 70 years of age, and 56% of the
participants were male. Most participants did not live alone,
were not working, and did not have dependent family mem-
bers. The time of diagnosis was most frequently more than 4
years ago, and 70% of the participants had received at least
two lines of treatment. Forty-four percent of the participants
were waiting to start (for instance, newly diagnosed or
between therapies) or receiving treatment.
Distribution of Individual Preferences
The subject-level part-worth values of each attribute level are
summarized in Figure 2, and the joint distribution of the attrib-
ute weights is displayed in Figure 3. The part worth associated
with the attributes’ least preferred attribute values is normal-
ized to 0 and thus the same for all participants. The part-worth
values of the other attribute levels within an attribute are
scaled according to how important these attribute levels are
compared with the least preferred attribute level. The part
worth associated with an attribute’s most preferred attribute
value is equal to the weight of that attribute and is scaled
according to how important the swing from the least preferred
to the most preferred attribute level is compared with the
swings from worst to best on the other attributes.
4 Patient Preferences for Multiple Myeloma Treatment Outcomes
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Figure 2 shows that the median (quartile 1 to quartile 3
range) weights given to PFS, mild or moderate chronic toxicity,
and severe or life-threatening toxicity were 0.53 (0.39–0.74),
0.11 (0.05–0.18), and 0.28 (0.134–0.44), respectively. For 58%
of the participants, the weight given to PFS exceeded the
cumulative weight given to the two toxicity attributes, meaning
that the majority of participants considered increasing the
probability of being progression-free for 1 year or longer
from 50% to 90% to be more important than simultaneously
decreasing the probability of experiencing severe or life-
threatening toxicity from 80% to 20% and the probability of
experiencing mild or moderate chronic toxicity from 85% to
45%. In Figure 3, this corresponds to all points that lie above
the horizontal gridline at 0.5 on the axis displaying the weight
given to PFS. However, as is shown by the distribution of the
weights across the different colored areas of the ternary plot,
there was considerable heterogeneity among participants with
respect to the relative importance given to the two toxicities,
with 56% attaching a higher weight to severe or life-
threatening toxicity and 44% attaching a higher weight to mild
or moderate chronic toxicity.When comparing the demographic
and clinical characteristics of these groups (Table 3), we found






60 years or younger 31%
61 to 70 years 44%
71 years and older 25%
White 97%
Working (full-time or part-time) 26%
Living alone 15%
Looking after dependent family members 14%
Time of diagnosis
Less than 2 years ago 23%
Between 2 and 4 years ago 24%
More than 4 years ago 53%
Current status
Awaiting or receiving treatment 44%
In remission or not requiring treatment 56%
Previous treatments
Fewer than two lines of treatment 30%
Two or more lines of treatment 70%
Side effects
None or mild/moderate, lasting for up to 2 months 31%
Mild/moderate, lasting more than 2 months 57%
Severe/life-threatening 12%
Regular contact with a patient organization/support group 45%
Other chronic health problems 32%
Figure 2. Part worth associated with the different levels for each attribute. The red points represent the average (mean) part worth at
each attribute level.
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that participants who gave a higher weight to severe or life-
threatening toxicity were more frequently age 70 or younger,
working, and looking after dependent family members and had
more frequently experienced severe or life-threatening side
effects. The demographic and clinical characteristics did not dif-
fer signiﬁcantly among those giving a higher weight to PFS and
those giving a higher cumulative weight to the two toxicities.
Decision Analysis Example
The probability of being progression-free for 1 year or longer
was 66% for the ixazomib-containing regimen and 59% for the
placebo-containing regimen [5], the probability of experiencing
mild or moderate chronic toxicity was 71% for the ixazomib-
containing regimen and 69% for the for the placebo-containing
regimen, and the probability of experiencing severe or life-
threatening toxicity was 60% for the ixazomib-containing regi-
men and 53% for the placebo-containing regimen (data
received on ﬁle from Takeda Pharma A/S, the marketing author-
ization holder for Ninlaro [ixazomib]). Based on these effect
sizes and the distribution of the individual preferences in the
surveyed population, following decision analysis, the propor-
tion of patients ranking the ixazomib-containing regimen above
the placebo-containing regimen was 76%.
Participant Feedback
In total, 261 participants (47%) provided free-text comments
about the survey. Out of those participants, 31% mentioned
that they found some of the questions difﬁcult to understand,
while 8% stated that they found the questionnaire easy to com-
prehend. There were also some participants who mentioned
that the instructions were clear but that the questions them-
selves were not always easy to answer and that as such the
questionnaire was thought-provoking and sometimes even a
bit upsetting. Others pointed to the mathematical nature of
the questions and that this resulted in the exercise feeling
rather academic. Finally, there were several participants who
mentioned that some of the questions were a bit repetitive
and that they therefore felt that the questionnaire could have
been shorter.
DISCUSSION
To understand the preferences of patients with multiple
myeloma for the beneﬁts and risks of treatments, we con-
ducted an online survey based on MCDA with 560 participants
from the cancer charity Myeloma UK. We found that the aver-
age weight given to PFS was higher than the average cumula-
tive weight given to the two toxicity attributes. The amount of
weight given to PFS was not associated with any of the col-
lected covariates. However, there was considerable heteroge-
neity with respect to the relative importance given to those
two toxicities, with participants who gave a higher weight to
severe or life-threatening toxicity more frequently being
younger, working, and looking after dependent family members
and having more frequently experienced severe or life-
threatening side effects.
M€uhlbacher et al. [6] previously conducted a discrete
choice experiment to elicit patients’ preferences for eight differ-
ent attributes associated with the treatment of multiple
myeloma. In their study, the possibility of having further treat-
ment options and life expectancy was considered to be the
most important attribute, while adverse events—ranging from
short-term, transient to long-term, permanent—were consid-
ered to be the least important attribute. The authors also found
that preferences only varied slightly in different subgroups of
patients, which is similar to what we found when comparing
the weight given to PFS with the cumulative weight given to
the two toxicities. However, because they only included one
generic toxicity attribute, they were not able to assess the rela-
tive importance of different types of toxicity as we did in our
study. It is here that we found larger differences in preferences
across different subgroups of patients.
Previous patient preference studies in oncology have gener-
ally assessed trade-offs over a wider range of attributes, includ-
ing aspects such as route of administration [7], cost of
treatment [8], and length of therapy-free intervals [6].While all
of these attributes are likely to be important considerations in
the setting of shared decision-making, whereby patients and
health care professionals decide together the best course of
action, one should strike a balance between number of attrib-
utes and total length of the survey. Furthermore, regulatory
decision-making is more narrowly focused on establishing the
beneﬁt-risk balance of the products under evaluation to the
exclusion of economic considerations. These are the reasons
why we only included attributes related to key measures of
clinical efﬁcacy and safety in our survey.
A second important consideration is the selection and oper-
ationalization of these attributes. In multiple myeloma, quality
of response, PFS, and overall survival are all well-established
efﬁcacy endpoints. However, because the former two end-
points are generally considered to be related to the latter, they
Figure 3. Ternary plot showing the joint distribution of the attrib-
ute weights. The left axis displays the weight given to mild or mod-
erate chronic toxicity, the right axis displays the weight given to
PFS, and the bottom axis displays the weight given to severe or
life-threatening toxicity. The black points represent the attribute
weights of the individual study participants, and the red diamond
represents the average weight given to the three attributes (0.54
for PFS, 0.32 for severe or life-threatening toxicity, and 0.14 for
mild or moderate chronic toxicity). The colored polygons represent
areas with a different ordinal ranking of the attribute weights.
Abbreviations: mod, moderate chronic toxicity; PFS, progression-
free survival; sev, severe toxicity.
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should not be simultaneously included as attributes in a multi-
criteria model [9]. This is both to ensure that the weights given
to the different attributes still have a clear interpretation and
to prevent participants from being confronted with seemingly
absurd trade-off questions, such as what duration of overall
survival they would be willing to forgo to increase the duration
of PFS by a speciﬁc amount. Patients participating in the focus
group at the start of the study considered it more relevant to
think in terms of time spent with the disease being under con-
trol or in remission than to think in terms of overall survival.
They also thought that formulating the elicitation questions in
terms of duration of the disease being under control might be
less upsetting to some participants. For these reasons, we
decided to focus on PFS in our study. The toxicities were aggre-
gated into two generic categories to ensure that our results
would be independent of the safety proﬁles of speciﬁc multiple
myeloma treatments and therefore more generally applicable
when assessing acceptability of treatments. For a more detailed
discussion of the pros and cons of aggregating the toxicities
into two generic categories rather than including multiple indi-
vidual side effects, we refer to Postmus et al [3].
Although the survey was built after extensive discussion
and pretesting to optimize contextual information provided
and the wording of the elicitation questions, it emerged
from the free-text comments at the end of the questionnaire
that there was still a group of participants who struggled to
understand these questions. It is therefore recommended
that further reﬁnements to the survey should aim to make it
more user friendly. For example, eliciting weights about
probability may be replaced by actual effects (e.g., speciﬁc
values for the duration of PFS instead of the probability that
the duration of PFS exceeds a certain time point), or the
mode of administration could be changed from online self-
administered to interviewer-guided, which is already a stand-
ard way of working in decision support approaches such as
decision conferencing [10]. However, such more elaborate
elicitation approaches are challenging in a survey-based set-
ting where the objective is to collect preference statements
from a large number of geographically dispersed individuals.
A limitation of this study is that we did not collect any infor-
mation on level of education or psychosocial and cognitive
factors, meaning that we were not able to further explore
how the construction and elicitation of the preferences
might have been affected by factors such as health literacy,
numeracy, and the willingness of patients to actively engage
in the medical decision-making.
Table 3. Comparison of the demographic and clinical characteristics between those giving a higher weight to mild or mod-







more important (n5 315) p value
Men 52% 59% .11
Age <.001
60 years or younger 26% 35%
61 to 70 years 41% 47%
71 years and older 33% 18%
White 97% 97% .61
Working (full-time or part-time) 19% 31% .003
Living alone 15% 14% .72
Looking after dependent family members 10% 17% .013
Time of diagnosis .76
Less than 2 years ago 23% 23%
Between 2 and 4 years ago 26% 23%
More than 4 years ago 51% 54%
Current status .13
Awaiting or receiving treatment 47% 41%
In remission or not requiring treatment 53% 59%
Previous treatments .074
Less than two lines of treatment 26% 33%
Two or more lines of treatment 74% 67%
Side effects .033
None or mild/moderate, lasting for up to 2 months 30% 32%
Mild/moderate, lasting more than 2 months 62% 53%
Severe/life-threatening 8% 15%
Regular contact with a patient organization/support group 45% 45% 1
Other chronic health problems 35% 31% .37
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The decision analysis example based on ixazomib showed
how quantitative preference statements from a larger group of
patients could be used in practice by different decision makers
when evaluating new treatments.While the example illustrates
the use of the method, it should not be considered to replace a
comprehensive beneﬁt-risk analysis of the ixazomib combina-
tion regimen, as a number of important aspects would require
further consideration. First, the Kaplan-Meier survival curves of
ixazomib and placebo for PFS started to separate relatively late,
with larger differences observed at later time points [5].
Because the beneﬁt-risk assessment was conducted with
1-year PFS as the measure of treatment efﬁcacy, this may have
resulted in a possible underrepresentation of the overall treat-
ment effect of ixazomib. Second, as intermittent adverse events
were reported as ongoing in our example, the estimates of the
proportion of patients experiencing mild or moderate chronic
toxicity were likely to include not only adverse events of
expected long duration, such as neuropathy, but also intermit-
tent adverse events, such as gastrointestinal events. Finally, the
observation time was longer for the ixazomib group, resulting
in larger differences in the adverse event rates between the
two study groups than what would have been obtained if equal
observation times and subsequent treatments were to be con-
sidered. Most of these limitations could be addressed using fur-
ther analyses and assumptions, but this was beyond the
purpose of this paper. To allow for further analyses, the empiri-
cal distribution of the subject-level preferences as well as an
accompanying R script ﬁle is available online [11].
CONCLUSION
This study demonstrated how quantitative preference state-
ments from a large group of participants with multiple
myeloma can be collected through an online survey and how
such information may be used to explore the heterogeneity of
preferences in the population, to identify subgroups with simi-
lar preferences, and to estimate the acceptability of speciﬁc
treatments. Although the usefulness of stated preference stud-
ies in drug regulation is still not well established, such studies,
along with other methods such as focus groups and expert
opinions, have the potential to become an important tool for
gathering patient views in a systematic way to inform regula-
tory and treatment decisions.
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